Saghmos Therapeutics, INC.
Bio-pharmaceutical company
Based in CT
🤖
AI Overview
With $280K in lobbying spend across 11 quarterly filings, Saghmos Therapeutics, INC is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2020 to 2022.
$280K
Total Spend
3
Years Active
1
Firms Hired
4
Lobbyists Deployed
2
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2020 | $150K |
| 2021 | $130K |
| 2022 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid
- •induced acute kidney injury
- •Prevention of contrast-induced acute kidney injury and major adverse renal and cardiac events after percutaneous coronary intervention.
- •Issues related to the policies proposed in the 21st Century Cures 2.0 Concept Paper. Education; and awareness, generally, regarding treatment of contrast-induced acute kidney injury after percutaneous
- •Medicare beneficiary access to a potential treatment to prevent contrast-induced acute kidney injury and major adverse renal and cardiac events after percutaneous coronary intervention, as well as pot
- •Issues related to the policies proposed in the 21st Century Cures 2.0 Concept Paper. Education and awareness, generally, regarding treatment of contrast-induced acute kidney injury after percutaneous
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.